Pfizer's Oral Abroctinib Bests Injectable Dupixent In Atopic Dermatitis Trial

 
• By Jessica Merrill

Only top-line data were released by Pfizer, and the safety of abrocitinib, like other JAK inhibitors, could remain an issue.

Comparison scale
Pfizer says abrocitinib performed better than Dupixent in a Phase III trial • Source: Alamy

More from Immunological

More from Therapy Areas